RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome.

IF 6.5 2区医学 Q1 IMMUNOLOGY

Oncoimmunology Pub Date : 2024-12-31 Epub Date: 2024-11-04 DOI:10.1080/2162402X.2024.2425465

Jonathan G Pol, Andrea Checcoli, Manuela Lizarralde-Guerrero, Guido Kroemer

引用次数: 0

Abstract

Apoptosis, necroptosis and pro-inflammatory NF-κB-dependent signaling are repressed by receptor-interacting serine/threonine-protein kinase 1 (RIPK1). A recent paper in Immunity describes a small molecule inducing the proteolytic degradation of RIPK1. In preclinical experiments, this RIPK1 inhibitor improved the anticancer efficacy of radiotherapy, immunotherapy (with PD-1 blockade) and radioimmunotherapy (with CTLA-4 blockade).

查看原文本刊更多论文

抑制恶性细胞中的 RIPK1 可增强免疫疗法和放疗效果。

受体丝氨酸/苏氨酸蛋白激酶1（RIPK1）可抑制细胞凋亡、坏死和依赖于NF-κB的促炎信号传导。最近发表在《免疫》（Immunity）杂志上的一篇论文介绍了一种诱导 RIPK1 蛋白质解体降解的小分子。在临床前实验中，这种 RIPK1 抑制剂提高了放疗、免疫疗法（PD-1 阻断）和放射免疫疗法（CTLA-4 阻断）的抗癌疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

12.50

自引率

2.80%

发文量

276

审稿时长

24 weeks

期刊介绍： OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.